Skip to main content

Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Publication ,  Journal Article
Wierda, WG; Byrd, JC; Abramson, JS; Bhat, S; Bociek, G; Brander, D; Brown, J; Chanan-Khan, A; Coutre, SE; Davis, RS; Fletcher, CD; Hill, B ...
Published in: J Natl Compr Canc Netw
November 2017

Hairy cell leukemia (HCL) is a rare type of indolent B-cell leukemia, characterized by symptoms of fatigue and weakness, organomegaly, pancytopenia, and recurrent opportunistic infections. Classic HCL should be considered a distinct clinical entity separate from HCLvariant (HCLv), which is associated with a more aggressive disease course and may not respond to standard HCL therapies. Somatic hypermutation in the IGHV gene is present in most patients with HCL. The BRAF V600E mutation has been reported in most patients with classic HCL but not in those with other B-cell leukemias or lymphomas. Therefore, it is necessary to distinguish HCLv from classic HCL. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of classic HCL.

Duke Scholars

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

November 2017

Volume

15

Issue

11

Start / End Page

1414 / 1427

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Proto-Oncogene Proteins B-raf
  • Oncology & Carcinogenesis
  • Mutation
  • Leukemia, Hairy Cell
  • Leukemia, B-Cell
  • Immunophenotyping
  • Immunoglobulin Heavy Chains
  • Humans
  • Gene Rearrangement
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wierda, W. G., Byrd, J. C., Abramson, J. S., Bhat, S., Bociek, G., Brander, D., … Sundar, H. (2017). Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 15(11), 1414–1427. https://doi.org/10.6004/jnccn.2017.0165
Wierda, William G., John C. Byrd, Jeremy S. Abramson, Seema Bhat, Greg Bociek, Danielle Brander, Jennifer Brown, et al. “Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw 15, no. 11 (November 2017): 1414–27. https://doi.org/10.6004/jnccn.2017.0165.
Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, et al. Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Nov;15(11):1414–27.
Wierda, William G., et al. “Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw, vol. 15, no. 11, Nov. 2017, pp. 1414–27. Pubmed, doi:10.6004/jnccn.2017.0165.
Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lancet J, Ma S, Malek S, Mosse C, Shadman M, Siddiqi T, Stephens D, Wagner N, Zelenetz AD, Dwyer MA, Sundar H. Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Nov;15(11):1414–1427.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

November 2017

Volume

15

Issue

11

Start / End Page

1414 / 1427

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Proto-Oncogene Proteins B-raf
  • Oncology & Carcinogenesis
  • Mutation
  • Leukemia, Hairy Cell
  • Leukemia, B-Cell
  • Immunophenotyping
  • Immunoglobulin Heavy Chains
  • Humans
  • Gene Rearrangement